diplomsko delo
Laura Rak (Author), Jernej Ogorevc (Mentor)

Abstract

Mutacije v genu za β-globin (HBB) so vzrok za β-hemoglobinopatije, ki sodijo med najpogostejše avtosomalno recesivno podedovane monogenske bolezni na svetu. Moderne tehnologije preurejanja genoma kot je CRISPR/Cas9, nam omogočajo preurejanje krvotvornih matičnih celic (KMC), ki jih lahko uporabimo za zdravljenje npr. anemije srpastih celic in β-talasemije, ki predstavljata resen zdravstveni problem. Strategije preurejanja temeljijo na odvzemu bolniku lastnih KMC in preureditvi le teh ex vivo. Glavni strategiji preurejanja, ki se uporabljata sta korekcija mutacij, ki so odgovorne za bolezensko stanje v HBB genu s pomočjo homologne rekombinacije ali reaktivacija izražanja γ-globina, ki vodi v ponovno nastajanje fetalnega hemoglobina, kar lahko dosežemo z vnosom mutacij, ki delujejo na glavni regulator nastajanja γ-globina - BCL11A, ali pa na njegove eritroidno specifične ojačevalce. Po preurejanju genoma uspešno preurejene celice transplantiramo nazaj v bolnika. Možna pa je tudi uporaba alogene transplantacije, kjer se v bolnika transplantira zdrave celice histokompatibilnega darovalca. Dokaj enostavna izolacija in pridobivanje KMC sta omogočila napredek v razvoju genetskih terapij vse do kliničnih raziskav z obetavnimi rezultati.

Keywords

CRISPR/Cas9;hemoglobinopatije;anemija srpastih celic;krvotvorne matične celice;

Data

Language: Slovenian
Year of publishing:
Typology: 2.11 - Undergraduate Thesis
Organization: UL BF - Biotechnical Faculty
Publisher: [L. Rak]
UDC: 606:616-056.7:616.155.194:616.155.16:602.9(043.2)
COBISS: 75447043 Link will open in a new window
Views: 290
Downloads: 33
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: English
Secondary title: Potential treatments of hemoglobinopathies using CRISPR/Cas9
Secondary abstract: Mutations in the β-globin (HBB) gene are the cause of β-hemoglobinopathies, which are one of the most common autosomal recessive inherited monogenic disorder in the world. Modern genome editing technologies such as CRISPR/Cas9 allow us to edit hematopoietic stem cells (HSCs) in a way they can be used to treat disorders like sickle cell anemia and β-thalassemia, which represent a growing health problem. The editing strategy is based on collecting patient's own HSCs and perform editing ex vivo. The main rearrangement strategies are: correction of the mutation responsible for the disease in the HBB gene by homologous recombination or reactivation of γ-globin expression, which enables formation of fetal hemoglobin; this is achieved by inducing mutations in the main regulator of γ-globin formation - BCL11A or in its erythroid-specific enhancers. After gene editing, the successfully edited cells are transplanted back into the patient. It is also possible to use allogeneic transplantation, where healthy cells of a histocompatible donor are transplanted into the patient. Simple isolation and collection of HSCs have enabled the advancement of genetic therapies all the way to clinical trials with promising results.
Secondary keywords: hemogloinopathies;sickle cell anemia;hematopoietic stem cells;
Type (COBISS): Bachelor thesis/paper
Study programme: 0
Thesis comment: Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije
Pages: VI, 21 str.
ID: 13335665